Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
REGN5668 + Cemiplimab/REGN4018 for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Chicago, Illinois
This trial is testing the safety and efficacy of two drugs, REGN5668 and cemiplimab, in combination with each other or with another drug, REGN4018. The primary objective is to assess the safety and tolerability of the combinations and to determine the maximally tolerated dose. The secondary objectives are to assess the preliminary efficacy of the combinations and to characterize the safety profile and pharmacokinetics of the combinations.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service